RETRACTED: TNFAIP8 Promotes Cisplatin Chemoresistance in Triple-Negative Breast Cancer by Repressing p53-Mediated miR-205-5p Expression (Retracted Article)

被引:8
作者
Ma, Hong-Yu [1 ]
Li, Yan [1 ]
Yin, Hui-Zi [1 ]
Yin, Hang [1 ]
Qu, Yuan-Yuan [1 ]
Xu, Qing-Yong [1 ]
机构
[1] Harbin Med Univ, Dept Breast Radiotherapy, Canc Hosp, 150 Haping Rd, Harbin 150081, Heilongjiang, Peoples R China
来源
MOLECULAR THERAPY NUCLEIC ACIDS | 2020年 / 22卷
关键词
NF-KAPPA-B; CELL-SURVIVAL; RESISTANCE; OVEREXPRESSION; P53; PROLIFERATION;
D O I
10.1016/j.omtn.2020.09.025
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Tumor necrosis factor alpha-induced protein 8 (TNFAIP8) is implicated in the tumor progression and prognosis of triple-negative breast cancer (TNBC), but the detailed regulatory mechanism of TNFAIP8 in cisplatin tolerance in TNBC has not yet been investigated. TNFAIP8 was evidently upregulated in TNBC tumor tissues and cell lines. Knocking down TNFAIP8 led to impaired proliferation and elevated apoptosis of TNBC cells upon cisplatin (DDP) treatment. Mechanistic studies revealed that TNFAIP8 repressed the expression of p53 and p53-promoted microRNA (miR)-205-5p; moreover, miR-205-5p targeted multiple genes required for the cell cycle and repressed Akt phosphorylation, which thus inhibited the proliferation of TNBC cells. In addition, silencing of TNFAIP8 led to the upregulation of miR-205-5p and the restraint of the TRAF2-NF-KB pathway, which thus enhanced the suppressive effects of DDP on tumor growth in nude mice. This study revealed that TNFAIP8 was essential in the DDP tolerance formation of TNBC cells by reducing p53-promoted miR-205-5p expression. Thus, targeting TNFAIP8 might become a promising strategy to suppress TNBC progression.
引用
收藏
页码:640 / 656
页数:17
相关论文
共 29 条
  • [1] NFκB mediates cisplatin resistance through histone modifications in head and neck squamous cell carcinoma (HNSCC)
    Almeida, Luciana O.
    Abrahao, Aline C.
    Rosselli-Murai, Luciana K.
    Giudice, Fernanda S.
    Zagni, Chiara
    Leopoldino, Andreia M.
    Squarize, Cristiane H.
    Castilho, Rogerio M.
    [J]. FEBS OPEN BIO, 2014, 4 : 96 - 104
  • [2] American Cancer Society, 2018, FACTS FIG 2018
  • [3] American Cancer Society, 2017, CANC FACTS FIG 2017
  • [4] [Anonymous], 2018, ANTI-CANCER DRUG, DOI [DOI 10.1097/CAD.0000000000000617, DOI 10.3322/caac.20115]
  • [5] Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
    Bianchini, Giampaolo
    Balko, Justin M.
    Mayer, Ingrid A.
    Sanders, Melinda E.
    Gianni, Luca
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (11) : 674 - 690
  • [6] TRAF2 multitasking in TNF receptor-induced signaling to NF-κB, MAP kinases and cell death
    Borghi, Alice
    Verstrepen, Lynn
    Beyaert, Rudi
    [J]. BIOCHEMICAL PHARMACOLOGY, 2016, 116 : 1 - 10
  • [7] Day TF, 2017, METHODS MOL BIOL, V1513, P83, DOI 10.1007/978-1-4939-6539-7_7
  • [8] miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance
    De Cola, A.
    Volpe, S.
    Budani, M. C.
    Ferracin, M.
    Lattanzio, R.
    Turdo, A.
    D'Agostino, D.
    Capone, E.
    Stassi, G.
    Todaro, M.
    Di Ilio, C.
    Sala, G.
    Piantelli, M.
    Negrini, M.
    Veronese, A.
    De laurenzi, V.
    [J]. CELL DEATH & DISEASE, 2015, 6 : e1823 - e1823
  • [9] A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness
    di Gennaro, Alessandra
    Damiano, Valentina
    Brisotto, Giulia
    Armellin, Michela
    Perin, Tiziana
    Zucchetto, Antonella
    Guardascione, Michela
    Spaink, Herman P.
    Doglioni, Claudio
    Snaar-Jagalska, B. Ewa
    Santarosa, Manuela
    Maestro, Roberta
    [J]. CELL DEATH AND DIFFERENTIATION, 2018, 25 (12) : 2165 - 2180
  • [10] MicroRNAs in Cancer
    Di Leva, Gianpiero
    Garofalo, Michela
    Croce, Carlo M.
    [J]. ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 9, 2014, 9 : 287 - 314